JPWO2022059785A1 - - Google Patents
Info
- Publication number
- JPWO2022059785A1 JPWO2022059785A1 JP2022550635A JP2022550635A JPWO2022059785A1 JP WO2022059785 A1 JPWO2022059785 A1 JP WO2022059785A1 JP 2022550635 A JP2022550635 A JP 2022550635A JP 2022550635 A JP2022550635 A JP 2022550635A JP WO2022059785 A1 JPWO2022059785 A1 JP WO2022059785A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020157940 | 2020-09-18 | ||
| PCT/JP2021/034399 WO2022059785A1 (ja) | 2020-09-18 | 2021-09-17 | 免疫チェックポイント阻害剤に対する応答を予測する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2022059785A1 true JPWO2022059785A1 (https=) | 2022-03-24 |
Family
ID=80776174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550635A Pending JPWO2022059785A1 (https=) | 2020-09-18 | 2021-09-17 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPWO2022059785A1 (https=) |
| TW (1) | TW202227643A (https=) |
| WO (1) | WO2022059785A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025048570A1 (ko) * | 2023-08-31 | 2025-03-06 | 의료법인 성광의료재단 | 신장암에서 면역 관문 억제제의 치료 반응성 예측 마커 및 이를 이용한 치료 반응성 예측 방법 |
| EP4617665A1 (en) * | 2024-03-14 | 2025-09-17 | Centre National de la Recherche Scientifique | An in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large b-cell lymphoma |
| WO2025191110A1 (en) * | 2024-03-14 | 2025-09-18 | Centre National De La Recherche Scientifique | An in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large b-cell lymphoma |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016175275A1 (ja) * | 2015-04-30 | 2016-11-03 | 国立大学法人京都大学 | Pd-l1(cd274)の異常を指標としたpd-1/pd-l1阻害剤の治療効果予測方法 |
| JP2018505658A (ja) * | 2014-12-09 | 2018-03-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Pd−1アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法 |
| WO2019191390A2 (en) * | 2018-03-28 | 2019-10-03 | Seres Therapeutics, Inc. | Treatment of a cancer by microbiome modulation |
| WO2019230919A1 (ja) * | 2018-05-31 | 2019-12-05 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
| JP2020500151A (ja) * | 2016-09-27 | 2020-01-09 | ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
| WO2020106983A1 (en) * | 2018-11-21 | 2020-05-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer |
-
2021
- 2021-09-17 TW TW110134919A patent/TW202227643A/zh unknown
- 2021-09-17 JP JP2022550635A patent/JPWO2022059785A1/ja active Pending
- 2021-09-17 WO PCT/JP2021/034399 patent/WO2022059785A1/ja not_active Ceased
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018505658A (ja) * | 2014-12-09 | 2018-03-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Pd−1アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法 |
| WO2016175275A1 (ja) * | 2015-04-30 | 2016-11-03 | 国立大学法人京都大学 | Pd-l1(cd274)の異常を指標としたpd-1/pd-l1阻害剤の治療効果予測方法 |
| JP2020500151A (ja) * | 2016-09-27 | 2020-01-09 | ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
| WO2019191390A2 (en) * | 2018-03-28 | 2019-10-03 | Seres Therapeutics, Inc. | Treatment of a cancer by microbiome modulation |
| WO2019230919A1 (ja) * | 2018-05-31 | 2019-12-05 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
| WO2020106983A1 (en) * | 2018-11-21 | 2020-05-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer |
Non-Patent Citations (3)
| Title |
|---|
| SONG, P. ET AL.: "Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy i", THORACIC CANCER, vol. 11, JPN6021048556, 23 April 2020 (2020-04-23), pages 1621 - 1632, ISSN: 0005619156 * |
| ZHENG YI ET AL.: "Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carci", JOURNAL OF IMMUNOTHERAPY OF CANCER, vol. 7, JPN6025023838, 2019, pages 193, ISSN: 0005619158 * |
| 市川将隆,他: "腸内細菌と免疫および悪性腫瘍との関連", 癌と化学療法, vol. 46, no. 12, JPN6021048555, 2019, pages 1807 - 1813, ISSN: 0005619157 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202227643A (zh) | 2022-07-16 |
| WO2022059785A1 (ja) | 2022-03-24 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A801 Effective date: 20230317 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230331 |
|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20230417 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250617 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251016 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260226 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260428 |